Citations (97)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Dieudonné Buh Kum, Niraj Mishra, Bram Vrancken, Hendrik Jan Thibaut, Annelies Wilder-Smith, Philippe Lemey, Johan Neyts & Kai Dallmeier. (2019) Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerging Microbes & Infections 8:1, pages 1734-1746.
Read now
Read now
Raphaëlle Klitting, Laura Roth, Félix A. Rey & Xavier de Lamballerie. (2018) Molecular determinants of Yellow Fever Virus pathogenicity in Syrian Golden Hamsters: one mutation away from virulence. Emerging Microbes & Infections 7:1, pages 1-18.
Read now
Read now
Clarissa de Castro Ferreira, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhāes, Christiane Costa-Pereira, Cleandro Pires de Albuquerque, Luciana Feitosa Muniz, Talita Yokoy de Souza, Ana Cristina Vanderley Oliveira, Olindo Assis Martins-Filho & Licia Maria Henrique da Mota. (2018) The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Review of Vaccines 17:1, pages 79-90.
Read now
Read now
Ian J. Amanna & Mark K. Slifka. (2016) Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Review of Vaccines 15:12, pages 1519-1533.
Read now
Read now
Stephen J. Seligman & Jean-Laurent Casanova. (2016) Yellow fever vaccine: worthy friend or stealthy foe?. Expert Review of Vaccines 15:6, pages 681-691.
Read now
Read now
Christian Herzog. (2014) Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Review of Vaccines 13:3, pages 399-415.
Read now
Read now
Pascale Cottin, Matthias Niedrig & Cristina Domingo. (2013) Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Review of Vaccines 12:11, pages 1351-1368.
Read now
Read now
Lin H Chen, Karin Leder & Mary E Wilson. (2013) Business travelers: vaccination considerations for this population. Expert Review of Vaccines 12:4, pages 453-466.
Read now
Read now
Articles from other publishers (89)
Andrea De Vito, Agnese Colpani, Mattia Trunfio, Vito Fiore, Giulia Moi, Marco Fois, Nicola Leoni, Stefano Ruiu, Sergio Babudieri, Andrea Calcagno & Giordano Madeddu. (2023) Living with HIV and Getting Vaccinated: A Narrative Review. Vaccines 11:5, pages 896.
Crossref
Crossref
Letícia Wigg de Araújo Lagos, Ariane de Jesus Lopes de Abreu, Rosângela Caetano & José Ueleres Braga. (2023) Yellow fever vaccine safety in immunocompromised individuals: a systematic review and meta-analysis. Journal of Travel Medicine 30:2.
Crossref
Crossref
Elizabeth D. Barnett, Phyllis E. Kozarsky & Robert Steffen. 2023. Plotkin's Vaccines. Plotkin's Vaccines
1450
1468.e6
.
Jose Tuells, Andrés F. Henao-Martínez & Carlos Franco-Paredes. (2022) Yellow Fever: A Perennial Threat. Archives of Medical Research 53:7, pages 649-657.
Crossref
Crossref
Thays Zanon Casagrande, Ismael Artur da Costa-Rocha, Maria Bernadete Renoldi de Oliveira Gavi, Samira Tatiyama Miyamoto, Priscila Costa Martins, Érica Vieira Serrano, Valquiria Garcia Dinis, Ketty Lysie Libardi Lira Machado, Sonia Alves Gouvea, Larissa Carvalho Caser, Ana Carolina Campi-Azevedo, Andréa Teixeira-Carvalho, Vanessa Peruhype-Magalhães, Maria de Fatima Bissoli, Maria da Penha Gomes Gouvea, Sheila Maria Barbosa de Lima, Emily Hime Miranda, Gisela Freitas Trindade, Danielle Grillo Pacheco Lyra, Ana Paula Neves Burian, Lauro Ferreira da Silva Pinto Neto, Licia Maria Henrique da Mota, Olindo Assis Martins-Filho & Valéria Valim. (2022) Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis. Vaccine 40:32, pages 4580-4593.
Crossref
Crossref
Li-Hsin Li, Laurens Liesenborghs, Lanjiao Wang, Marleen Lox, Michael Bright Yakass, Sander Jansen, Ana Lucia Rosales Rosas, Xin Zhang, Hendrik Jan Thibaut, Dirk Teuwen, Johan Neyts, Leen Delang & Kai Dallmeier. (2022) Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Molecular Therapy - Methods & Clinical Development 25, pages 215-224.
Crossref
Crossref
Ashwin Juneja. (2022) Travel health pharmacy: A new model for sustainability. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 155:3, pages 143-149.
Crossref
Crossref
Denise Haslwanter, Gorka Lasso, Anna Z. Wec, Nathália Dias Furtado, Lidiane Menezes Souza Raphael, Alexandra L. Tse, Yan Sun, Stephanie Stransky, Núria Pedreño-Lopez, Carolina Argondizo Correia, Zachary A. Bornholdt, Mrunal Sakharkar, Vivian I. Avelino-Silva, Crystal L. Moyer, David I. Watkins, Esper G. Kallas, Simone Sidoli, Laura M. Walker, Myrna C. Bonaldo & Kartik Chandran. (2022) Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies. Cell Host & Microbe 30:2, pages 248-259.e6.
Crossref
Crossref
Raj Palraj. 2022. A Rational Approach to Clinical Infectious Diseases. A Rational Approach to Clinical Infectious Diseases
200
219
.
Nadia Oreshkova, Sebenzile K. Myeni, Niraj Mishra, Irina C. Albulescu, Tim J. Dalebout, Eric J. Snijder, Peter J. Bredenbeek, Kai Dallmeier & Marjolein Kikkert. (2021) A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses. Vaccines 9:12, pages 1492.
Crossref
Crossref
Htay-Htay Han, Clemente Diaz, Camilo J Acosta, Mengya Liu & Astrid Borkowski. (2021) Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial. The Lancet Infectious Diseases 21:9, pages 1282-1292.
Crossref
Crossref
Fiona Ecarnot, Stefania Maggi, Jean-Pierre Michel, Nicola Veronese & Andrea Rossanese. (2021) Vaccines and Senior Travellers. Frontiers in Aging 2.
Crossref
Crossref
Jordana Rodrigues Barbosa Fradico, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, Jordana Grazziela Alves Coelho-dos-Reis, Elaine Spezialli Faria, Betânia Paiva Drumond, Izabela Maurício de Rezende, Janaina Fonseca Almeida, Roberta Barros da Silva, Josiane Dias Gusmão, Eva Lídia Arcoverde Medeiros, Regina Coeli Magalhães Rodrigues, José Geraldo Leite Ribeiro, Maira Alves Pereira, Marcos Vinícius Ferreira Silva, Marília Lima Cruz Rocha, Talita Emile Ribeiro Adelino, Felipe Campos de Melo Iani, Glauco Carvalho Pereira, Eder Gatti Fernandes, Maria Auxiliadora-Martins, Valéria Valim, Matheus de Souza Gomes, Laurence Rodrigues Amaral, Alessandro Pecego Martins Romano, Daniel Garkauskas Ramos, Sandra Maria Deotti Carvalho, Francieli Fontana Sutile Tardetti Fantinato, Rodrigo Fabiano do Carmo Said, Andréa Teixeira-Carvalho & Olindo Assis Martins-Filho. (2021) CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions. Vaccine 39:31, pages 4359-4372.
Crossref
Crossref
Ismael Artur da Costa-Rocha, Ketty Lysie Libardi Lira Machado, Ana Carolina Campi-Azevedo, Andréa Teixeira-Carvalho, Vanessa Peruhype-Magalhães, Sheila Maria Barbosa de Lima, Emily Hime Miranda, Gisela Freitas Trindade, Thays Zanon Casagrande, Samira Tatiyama Miyamoto, Sávio Carvalho Deotti, Rafaela Villa Real Barbosa, Priscila Costa Martins Rocha, Erica Vieira Serrano, Valquiria Garcia Dinis, Sônia Alves Gouvêa, Maria Bernadete Renoldi de Oliveira Gavi, Lidia Balarini da Silva, Ruben Horst Duque, Ana Paula Espíndula Gianordoli, Maria de Fatima Bissoli, Maria da Penha Gomes Gouvea, Lauro Ferreira da Silva Pinto-Neto, Ana Paula Neves Burian, Francieli Fontana Sutile Tardetti Fantinato, Gecilmara Salviato Pileggi, Licia Maria Henrique da Mota, Valéria Valim & Olindo Assis Martins-Filho. (2021) Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. Scientific Reports 11:1.
Crossref
Crossref
I.N. Abdullahi, A.U. Anka, A.U. Emeribe, K. Umar, H.A. Adekola, L. Uzairue, P.E. Ghmaba & C.C. Okwume. (2021) The interplay between environmental factors, vector competence and vaccine immunodynamics as possible explanation of the 2019 yellow fever re-emergence in Nigeria. New Microbes and New Infections 41, pages 100858.
Crossref
Crossref
Berengere Koehl, Camille Aupiais, Nelly Schinckel, Pierre Mornand, Marie-Hélène Odièvre, Assa Niakate, Valentine Brousse, Ghislaine Ithier, Florence Missud, Laurent Holvoet, Malika Benkerrou, Frederic Sorge & Albert Faye. (2021) Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study. Journal of Travel Medicine 28:3.
Crossref
Crossref
Carleigh B. Krubiner, Ruth R. Faden, Ruth A. Karron, Margaret O. Little, Anne D. Lyerly, Jon S. Abramson, Richard H. Beigi, Alejandro R. Cravioto, Anna P. Durbin, Bruce G. Gellin, Swati B. Gupta, David C. Kaslow, Sonali Kochhar, Florencia Luna, Carla Saenz, Jeanne S. Sheffield & Paulina O. Tindana. (2021) Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine 39:1, pages 85-120.
Crossref
Crossref
Natalie Prevatt & Ron H. Behrens. 2021. Pediatric Vaccines and Vaccinations. Pediatric Vaccines and Vaccinations
261
279
.
Amanda Makha Bifani, Eugenia Z. Ong & Ruklanthi de Alwis. (2020) Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever. Current Treatment Options in Infectious Diseases 12:4, pages 398-409.
Crossref
Crossref
Jose Mateus, Alba Grifoni, Hannah Voic, Michael A. Angelo, Elizabeth Phillips, Simon Mallal, John Sidney, Alessandro Sette & Daniela Weiskopf. (2020) Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. Viruses 12:11, pages 1300.
Crossref
Crossref
Hugo Arlegui, Kaatje Bollaerts, Francesco Salvo, Vincent Bauchau, Gaëlle Nachbaur, Bernard Bégaud & Nicolas Praet. (2020) Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines. Drug Safety 43:11, pages 1089-1104.
Crossref
Crossref
Amanda Makha Bifani, Eugenia Z. Ong & Ruklanthi de Alwis. (2020) Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever. Current Treatment Options in Infectious Diseases 12:3, pages 349-360.
Crossref
Crossref
Daniel A. Moreira, Alessandra P. Lamarca, Rafael Ferreira Soares, Ana M. A. Coelho, Carolina Furtado, Nicole M. Scherer, Miguel A. M. Moreira, Hector N. Seuánez & Mariana Boroni. (2020) Transcriptome of the Southern Muriqui Brachyteles arachnoides (Primates:Platyrrhini), a Critically Endangered New World Monkey: Evidence of Adaptive Evolution. Frontiers in Genetics 11.
Crossref
Crossref
Jenny G. LowJustin H.J. NgEugenia Z. OngShirin KalimuddinLimin WijayaYvonne F.Z. ChanDorothy H.L. NgHwee-Cheng TanAnjali BaglodyYok-Hian ChionhDebbie C.P. LeeYadunanda BudigiRam SasisekharanEng-Eong Ooi. (2020) Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody. New England Journal of Medicine 383:5, pages 452-459.
Crossref
Crossref
Valéria Valim, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, Arthur Dalmaso Pinto, Priscila Costa Martins Rocha, Erica Vieira Serrano, Valquiria Garcia Dinis, Sônia Alves Gouvêa, João Gabriel Fragoso Dias, Ana Carolina Campi-Azevedo, Andréa Teixeira-Carvalho, Vanessa Peruhype-Magalhães, Ismael Artur da Costa-Rocha, Sheila Maria Barbosa de Lima, Emily Hime Miranda, Gisela Freitas Trindade, Maria de Lourdes de Sousa Maia, Maria Bernadete Renoldi de Oliveira Gavi, Lidia Balarini da Silva, Ruben Horst Duque, Ana Paula Espíndula Gianordoli, Thays Zanon Casagrande, Karine Gadioli Oliveira, Bruna Costa da Mata Moura, Fernanda Nicole-Batista, Luiza Correa Rodrigues, Thalles Brandão Clemente, Enan Sales Magalhães, Maria de Fatima Bissoli, Maria da Penha Gomes Gouvea, Lauro Ferreira da Silva Pinto-Neto, Carolina Zorzanelli Costa, Raquel Altoé Giovelli, Leticia Resende Brandão, Elizandra Tomazela Laurenti Polito, Ingrid de Oliveira Koehlert, Brunela Passos Borjaille, Daniela Bergamim Pereira, Laiza Hombre Dias, Daniela Linhares Merlo, Luiz Fellipe Favoreto Genelhu, Flavia Zon Pretti, Maryella dos Santos Giacomin, Ana Paula Neves Burian, Francieli Fontana Sutile Tardetti Fantinato, Gecilmara Salviato Pileggi, Lícia Maria Henrique da Mota & Olindo Assis Martins-Filho. (2020) Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study. Frontiers in Immunology 11.
Crossref
Crossref
Elaine Reno, Nicolas G Quan, Carlos Franco-Paredes, Daniel B Chastain, Lakshmi Chauhan, Alfonso J Rodriguez-Morales & Andrés F Henao-Martínez. (2020) Prevention of yellow fever in travellers: an update. The Lancet Infectious Diseases 20:6, pages e129-e137.
Crossref
Crossref
Rafaela S. Fernandes, Marjorie C. L. C. Freire, Renata V. Bueno, Andre S. Godoy, Laura H. V. G. Gil & Glaucius Oliva. (2020) Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses. Viruses 12:6, pages 598.
Crossref
Crossref
Preety Kalra & Indu Ratti. (2020) Impact of Yellow Fever with Multiple Control Measures: Mathematical Model. Journal of Physics: Conference Series 1531:1, pages 012066.
Crossref
Crossref
Gabriela Dias Noske, Victor Oliveira Gawriljuk, Rafaela Sachetto Fernandes, Nathalia Dias Furtado, Myrna Cristina Bonaldo, Glaucius Oliva & Andre Schutzer Godoy. (2020) Structural characterization and polymorphism analysis of the NS2B-NS3 protease from the 2017 Brazilian circulating strain of Yellow Fever virus. Biochimica et Biophysica Acta (BBA) - General Subjects 1864:4, pages 129521.
Crossref
Crossref
Lígia C Pierrotti, Amaro N Duarte-Neto, Alice T W Song, Carlucci G Ventura, Elias David-Neto & Luiz S Azevedo. (2020) Fatal Yellow Fever in a Kidney Transplant Patient. Clinical Infectious Diseases 70:1, pages 144-148.
Crossref
Crossref
Gecilmara Salviato Pileggi, Licia Maria Henrique Da Mota, Adriana Maria Kakehasi, Alexandre Wagner De Souza, Aline Rocha, Ana Karla Guedes de Melo, Caroline Araujo M. da Fonte, Cecilia Bortoletto, Claiton Viegas Brenol, Claudia Diniz Lopes Marques, Cyrla Zaltman, Eduardo Ferreira Borba, Enio Ribeiro Reis, Eutilia Andrade Medeiros Freire, Evandro Mendes Klumb, Georges Basile Christopoulos, Ieda Maria M. Laurindo, Isabella Ballalai, Izaias Pereira Da Costa, Lessandra Michelin, Lilian David de Azevêdo Valadares, Liliana Andrade Chebli, Marcus Lacerda, Maria Amazile Ferreira Toscano, Michel Alexandre Yazbek, Rejane Maria R. De Abreu Vieira, Renata Magalhães, Renato Kfouri, Rosana Richtmann, Selma Da Costa Silva Merenlender, Valeria Valim, Marcos Renato De Assis, Sergio Candido Kowalski & Virginia Fernandes Moça Trevisani. (2019) Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Advances in Rheumatology 59:1.
Crossref
Crossref
Kay M. Tomashek, Mark Challberg, Seema U. Nayak & Helen F. Schiltz. (2019) Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?. Vaccines 7:4, pages 179.
Crossref
Crossref
Kuan Rong Chan, Esther Shuyi Gan, Candice Yuen Yue Chan, Cui Liang, John Zhong Heng Low, Summer Li-Xin Zhang, Eugenia Ziying Ong, Ashwin Bhatta, Limin Wijaya, Yie Hou Lee, Jenny Guek-Hong Low & Eng Eong Ooi. (2019) Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection. Nature Medicine 25:8, pages 1218-1224.
Crossref
Crossref
Tânia P. Pato, Marta C.O. Souza, Diogo A. Mattos, Elena Caride, Davis F. Ferreira, Luciane P. Gaspar, Marcos S. Freire & Leda R. Castilho. (2019) Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture. Vaccine 37:24, pages 3214-3220.
Crossref
Crossref
P. Pushko, А. А. Ishmukhametov, P. P. Bredenbeek & I. S. Lukashevich. (2019) Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever. Epidemiology and Vaccinal Prevention 18:1, pages 18-25.
Crossref
Crossref
Federico Perdomo-Celis, Maria S. Salvato, Sandra Medina-Moreno & Juan C. Zapata. (2019) T-Cell Response to Viral Hemorrhagic Fevers. Vaccines 7:1, pages 11.
Crossref
Crossref
Derick Kimathi, Aitana Juan, Philip Bejon, Rebecca F. Grais & George M. Warimwe. (2019) Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda. Wellcome Open Research 4, pages 182.
Crossref
Crossref
Christina Forstner, Anja Kwetkat, Benjamin Schleenvoigt & Mathias W. Pletz. (2018) Risikoimpfungen im AlterVaccinations in the elderly — who, when and which vaccine to use. MMW - Fortschritte der Medizin 160:21-22, pages 52-61.
Crossref
Crossref
Cristiane Pinheiro Pestana, Rafael Lawson-Ferreira, Carolina Lessa-Aquino, Maria da Luz Fernandes Leal, Marcos da Silva Freire, Akira Homma & Marco Alberto Medeiros. (2018) Sanger-based sequencing technology for yellow fever vaccine genetic quality control. Journal of Virological Methods 260, pages 82-87.
Crossref
Crossref
Raphaëlle Klitting, Carlo Fischer, Jan Drexler, Ernest Gould, David Roiz, Christophe Paupy & Xavier de Lamballerie. (2018) What Does the Future Hold for Yellow Fever Virus? (II). Genes 9:9, pages 425.
Crossref
Crossref
R Klitting, T Riziki, G Moureau, G Piorkowski, E A Gould & X de Lamballerie. (2018) Exploratory re-encoding of yellow fever virus genome: new insights for the design of live-attenuated viruses. Virus Evolution 4:2.
Crossref
Crossref
Michelle Larissa Zini Lise & Michael Laurence Zini Lise. (2018) Cutaneous lesions caused by the yellow fever vaccine – have you ever seen them?. Revista da Associação Médica Brasileira 64:6, pages 498-500.
Crossref
Crossref
Stephen TotteyYoko ShojiR. Mark JonesJessica A. ChichesterBrian J. GreenKonstantin MusiychukHuaxin SiSlobodanka D. MancevaAmy RheeMoneim ShamloulJoey NorikaneRosane C. Guimarães, Elena Caride, Andrea N. M. R. Silva, Marisol Simões, Patricia C. C. Neves, Renato Marchevsky, Marcos S. Freire, Stephen J. StreatfieldVidadi Yusibov. (2018) Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models. The American Journal of Tropical Medicine and Hygiene 98:2, pages 420-431.
Crossref
Crossref
Elizabeth D. Barnett, Phyllis E. Kozarsky & Robert Steffen. 2018. Plotkin's Vaccines. Plotkin's Vaccines
1383
1401.e6
.
Justin G Julander & Venkatraman Siddharthan. (2017) Small-Animal Models of Zika Virus. The Journal of Infectious Diseases 216:suppl_10, pages S919-S927.
Crossref
Crossref
Tim Niehues, Christian Bogdan, Jane Hecht, Thomas Mertens, Miriam Wiese-Posselt & Fred Zepp. (2017) Impfen bei Immundefizienz. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 60:6, pages 674-684.
Crossref
Crossref
Pieter Neels, James Southern, Jon Abramson, Philippe Duclos, Joachim Hombach, Melanie Marti, Alanna Fitzgerald-Husek, Jacqueline Fournier-Caruana & Germaine Hanquet. (2017) Off-label use of vaccines. Vaccine 35:18, pages 2329-2337.
Crossref
Crossref
Jolanta Florczak-Wyspiańska, Ewa Nawotczyńska & Wojciech Kozubski. (2017) Yellow fever vaccine-associated neurotropic disease (YEL-AND) – A case report. Neurologia i Neurochirurgia Polska 51:1, pages 101-105.
Crossref
Crossref
Lynne Margaret Webber. (2016) Yellow Fever: The Resurgence of a Forgotten Disease and HIV-Infected Travellers. Journal of Human Virology & Retrovirology 4:2.
Crossref
Crossref
Giovanni Rezza. (2016)
Vaccines against chikungunya, Zika and other emerging
Aedes
mosquito-borne viruses: unblocking existing bottlenecks
. Future Virology 11:11, pages 723-730.
Crossref
Crossref
Anna Maria Geretti, Gary Brook, Claire Cameron, David Chadwick, Neil French, Robert Heyderman, Antonia Ho, Michael Hunter, Shamez Ladhani, Mark Lawton, Eithne MacMahon, John McSorley, Anton Pozniak & Alison Rodger. (2016)
B
ritish
HIV A
ssociation Guidelines on the Use of Vaccines in
HIV
‐Positive Adults 2015
. HIV Medicine 17:S3.
Crossref
Crossref
Yu Cong, Monica A. McArthur, Melanie Cohen, Peter B. Jahrling, Krisztina B. Janosko, Nicole Josleyn, Kai Kang, Tengfei Zhang & Michael R. Holbrook. (2016) Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells. PLOS Neglected Tropical Diseases 10:5, pages e0004709.
Crossref
Crossref
Wai Shing Leung, Man Chun Chan, Shiu Hong Chik & Tak Yin Tsang. (2016) First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong: Table 1.. Journal of Travel Medicine 23:4, pages taw020.
Crossref
Crossref
Andreas H. Leischker. 2016. Developing Drug Products in an Aging Society. Developing Drug Products in an Aging Society
563
576
.
Axel Ronald Schulz, Julia Nora Mälzer, Cristina Domingo, Karsten Jürchott, Andreas Grützkau, Nina Babel, Mikalai Nienen, Tomas Jelinek, Matthias Niedrig & Andreas Thiel. (2015) Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans. The Journal of Immunology 195:10, pages 4699-4711.
Crossref
Crossref
Maud Salmona, Sandrine Gazaignes, Severine Mercier-Delarue, Fabienne Garnier, Jehanara Korimbocus, Nathalie Colin de Verdière, Jerome LeGoff, Pierre Roques & François Simon. (2015) Molecular characterization of the 17D-204 yellow fever vaccine. Vaccine 33:41, pages 5432-5436.
Crossref
Crossref
Renata C. Pereira, Andrea N.M.R. Silva, Marta Cristina O. Souza, Marlon V. Silva, Patrícia P.C.C. Neves, Andrea A.M.V. Silva, Denise D.C.S. Matos, Miguel A.O. Herrera, Anna M.Y. Yamamura, Marcos S. Freire, Luciane P. Gaspar & Elena Caride. (2015) An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine 33:35, pages 4261-4268.
Crossref
Crossref
Thomas P. Monath & Pedro F.C. Vasconcelos. (2015) Yellow fever. Journal of Clinical Virology 64, pages 160-173.
Crossref
Crossref
David W.C. Beasley, Alexander J. McAuley & Dennis A. Bente. (2015) Yellow fever virus: Genetic and phenotypic diversity and implications for detection, prevention and therapy. Antiviral Research 115, pages 48-70.
Crossref
Crossref
Carolyn Driver. (2015) Yellow fever vaccination changes. Independent Nurse 2015:3, pages 22-25.
Crossref
Crossref
Ana C. V. Oliveira, Licia M. H. Mota, Leopoldo L. Santos‐Neto, Marisol Simões, Olindo A. Martins‐Filho & Pedro L. Tauil. (2015) Seroconversion in Patients With Rheumatic Diseases Treated With Immunomodulators or Immunosuppressants, Who Were Inadvertently Revaccinated Against Yellow Fever. Arthritis & Rheumatology 67:2, pages 582-583.
Crossref
Crossref
Robert Steffen, Ron H. Behrens, David R. Hill, Christina Greenaway & Karin Leder. (2015) Vaccine‐Preventable Travel Health Risks: What Is the Evidence—What Are the Gaps?. Journal of Travel Medicine 22:1, pages 1-12.
Crossref
Crossref
Jonas Klingström & Clas Ahlm. 2015. Sex and Gender Differences in Infection and Treatments for Infectious Diseases. Sex and Gender Differences in Infection and Treatments for Infectious Diseases
211
230
.
Darci R. Smith, Michael R. Holbrook & Brian B. Gowen. (2014) Animal models of viral hemorrhagic fever. Antiviral Research 112, pages 59-79.
Crossref
Crossref
Flora Engelmann, Laurence Josset, Thomas Girke, Byung Park, Alex Barron, Jesse Dewane, Erika Hammarlund, Anne Lewis, Michael K. Axthelm, Mark K. Slifka & Ilhem Messaoudi. (2014) Pathophysiologic and Transcriptomic Analyses of Viscerotropic Yellow Fever in a Rhesus Macaque Model. PLoS Neglected Tropical Diseases 8:11, pages e3295.
Crossref
Crossref
Justin G. Julander, Shanta Bantia, Brian R. Taubenheim, Dena M. Minning, Pravin Kotian, John D. Morrey, Donald F. Smee, William P. Sheridan & Yarlagadda S. Babu. (2014) BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster Model. Antimicrobial Agents and Chemotherapy 58:11, pages 6607-6614.
Crossref
Crossref
Reinaldo de Menezes Martins, Ana Luiza Braz Pavão, Patrícia Mouta Nunes de Oliveira, Paulo Roberto Gomes dos Santos, Sandra Maria D. Carvalho, Renate Mohrdieck, Alexandre Ribeiro Fernandes, Helena Keico Sato, Patricia Mandali de Figueiredo, Vanessa dos Reis von Doellinger, Maria da Luz Fernandes Leal, Akira Homma & Maria de Lourdes S. Maia. (2014) Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil. Vaccine 32:49, pages 6676-6682.
Crossref
Crossref
Stephen J. Seligman. (2014) Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32:44, pages 5769-5775.
Crossref
Crossref
Swati Mukherjee, Kimberly A. Dowd, Carolyn J. Manhart, Julie E. Ledgerwood, Anna P. Durbin, Stephen S. Whitehead & Theodore C. Pierson. (2014) Mechanism and Significance of Cell Type-Dependent Neutralization of Flaviviruses. Journal of Virology 88:13, pages 7210-7220.
Crossref
Crossref
Helena H. Askling & Virgil A.S.H. Dalm. (2014) The medically immunocompromised adult traveler and pre-travel counseling: Status quo 2014. Travel Medicine and Infectious Disease 12:3, pages 219-228.
Crossref
Crossref
Cristián Biscayart, María Eugenia Pérez Carrega, Sandra Sagradini, Ángela Gentile, Daniel Stecher, Tomás Orduna, Silvia Bentancourt, Salvador García Jiménez, Luis Pedro Flynn, Gabriel Pirán Arce, María Andrea Uboldi, Laura Bugna, María Alejandra Morales, Clara Digilio, Cintia Fabbri, Delia Enría, Máximo Diosque & Carla Vizzotti. (2014) Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine 32:11, pages 1266-1272.
Crossref
Crossref
Mikio Kimura, Tatsuya Fujii & Bernadette Carroll. (2014) Prioritising immunisations for travel: International and Japanese perspectives. Travel Medicine and Infectious Disease 12:2, pages 118-128.
Crossref
Crossref
M. Montes de Oca Arjona, P. Martín Peral, M. Monsalvo Hernando & E. Ruiz Blasco. (2014) Infecciones víricas endémicas: dengue, fiebre del Nilo, otras. Medicine - Programa de Formación Médica Continuada Acreditado 11:50, pages 2965-2972.
Crossref
Crossref
Stephen J. Seligman, Jean-Laurent Casanova, John C. Pezzullo, Joel E. Cohen & Yuval Itan. (2014) Defining Risk Groups to Yellow Fever Vaccine-Associated Viscerotropic Disease in the Absence of Denominator Data. The American Journal of Tropical Medicine and Hygiene 90:2, pages 267-271.
Crossref
Crossref
F. Tangy & P. Despres. (2013) Yellow Fever Vaccine Attenuation Revealed: Loss of Diversity. Journal of Infectious Diseases 209:3, pages 318-320.
Crossref
Crossref
Jae-Min Yuk & Eun-Kyeong Jo. (2014) Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis. Clinical and Experimental Vaccine Research 3:2, pages 155.
Crossref
Crossref
Peter Pushko, Peter P. Bredenbeek & Igor S. Lukashevich. 2014. Novel Technologies for Vaccine Development. Novel Technologies for Vaccine Development
153
177
.
Eddie A. James, Rebecca E. LaFond, Theresa J. Gates, Duy T. Mai, Uma Malhotra & William W. Kwok. (2013)
Yellow Fever Vaccination Elicits Broad Functional CD4
+
T Cell Responses That Recognize Structural and Nonstructural Proteins
. Journal of Virology 87:23, pages 12794-12804.
Crossref
Crossref
Ellen Rafferty, Philippe Duclos, Sergio Yactayo & Melanie Schuster. (2013) Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review. Vaccine 31:49, pages 5798-5805.
Crossref
Crossref
Emile F. F. Jonker, Leonardus G. Visser & Anna H. Roukens. (2013) Advances and controversies in yellow fever vaccination. Therapeutic Advances in Vaccines 1:4, pages 144-152.
Crossref
Crossref
James D. Nordin, Emily D. Parker, Gabriela Vazquez‐Benitez, Elyse O. Kharbanda, Allison Naleway, S. Michael Marcy, Beth Molitor, Leslie Kuckler & James Baggs. (2013) Safety of the Yellow Fever Vaccine: A Retrospective Study. Journal of Travel Medicine 20:6, pages 368-373.
Crossref
Crossref
Dipti Patel & Hilary Simons. (2013) Yellow fever vaccination: Is one dose always enough?. Travel Medicine and Infectious Disease 11:5, pages 266-273.
Crossref
Crossref
Hector S. Izurieta, Patrick Zuber, Jan Bonhoeffer, Robert T. Chen, Osman Sankohg, Kayla F. Laserson, Miriam Sturkenboom, Christian Loucq, Daniel Weibel, Caitlin Dodd & Steve Black. (2013) Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines. Vaccine 31:35, pages 3623-3627.
Crossref
Crossref
Emily S. Jentes, Pauline Han, Mark D. Gershman, Sowmya R. Rao, Regina C. LaRocque, J. Erin Staples & Edward T. Ryan. (2013) Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009–2011. The American Journal of Tropical Medicine and Hygiene 88:5, pages 954-961.
Crossref
Crossref
Carolyn Driver. (2013) Yellow fever vaccination during pregnancy or breastfeeding. Practice Nursing 24:4, pages 174-178.
Crossref
Crossref
Lewis Markoff. (2013) Yellow Fever Outbreak in Sudan. New England Journal of Medicine 368:8, pages 689-691.
Crossref
Crossref
Biao Guo, Andrew Page, Huaqing Wang, Richard Taylor & Peter McIntyre. (2013) Systematic review of reporting rates of adverse events following immunization: An international comparison of post-marketing surveillance programs with reference to China. Vaccine 31:4, pages 603-617.
Crossref
Crossref
Gerd Burchard. (2012) „Sagen Sie mir Ihr Reiseziel, dann sage ich Ihnen, wogegen ich Sie impfe!“. MMW - Fortschritte der Medizin 154:18, pages 66-73.
Crossref
Crossref
Joanna S. Herman & David R. Hill. (2012) Vaccine-Preventable Diseases and Their Prophylaxis. Infectious Disease Clinics of North America 26:3, pages 595-608.
Crossref
Crossref